Palynziq
Total Payments
$14.8M
Transactions
4,358
Doctors
387
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $314,174 | 499 | 142 |
| 2023 | $3.2M | 1,045 | 135 |
| 2022 | $834,261 | 502 | 154 |
| 2021 | $609,342 | 262 | 78 |
| 2020 | $1.2M | 314 | 40 |
| 2019 | $4.3M | 1,070 | 71 |
| 2018 | $4.3M | 666 | 63 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.2M | 1,425 | 89.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $968,201 | 649 | 6.5% |
| Travel and Lodging | $303,582 | 910 | 2.0% |
| Grant | $136,179 | 20 | 0.9% |
| Consulting Fee | $102,816 | 45 | 0.7% |
| Food and Beverage | $75,305 | 1,282 | 0.5% |
| Education | $36,884 | 26 | 0.2% |
| Charitable Contribution | $12,000 | 1 | 0.1% |
Payments by Type
Research
$13.2M
1,425 transactions
General
$1.6M
2,933 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU Prism302 | BioMarin Pharmaceutical Inc. | $3.2M | 0 |
| Phase 3 substudy enrolling approximately 100 subjects aged 18 to 70 years old with PKU who are concurrently participating in the 165-302 study | BioMarin Pharmaceutical Inc. | $3.0M | 0 |
| Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU (Prism302) | BioMarin Pharmaceutical Inc. | $2.2M | 0 |
| An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dose) in Adults with Phenylketonuria | BioMarin Pharmaceutical Inc. | $922,223 | 0 |
| An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/day Dose) in Adults with Phenylketonuria | BioMarin Pharmaceutical Inc. | $894,945 | 0 |
| Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU PAL-003 | BioMarin Pharmaceutical Inc. | $617,222 | 0 |
| Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003) | BioMarin Pharmaceutical Inc. | $612,313 | 0 |
| An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dose) in Adults with Phenylketonuria | BioMarin Pharmaceutical Inc. | $310,427 | 0 |
| Nutrition Status of Adults Treated with Pegvaliase | BioMarin Pharmaceutical Inc. | $274,478 | 0 |
| An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dose in Adults with Phenylketonuria | BioMarin Pharmaceutical Inc. | $161,315 | 0 |
| Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU Prism302) | BioMarin Pharmaceutical Inc. | $154,928 | 0 |
| An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated W- BMN 165-Prism301 | BioMarin Pharmaceutical Inc. | $151,732 | 0 |
| A Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety and Tolerability of an Induction, Titration, and Maintenance Dose Regimen of BMN 165 Self Administered by Adults With Phenylketonuria Not Previously Treated with BMN 165 | BioMarin Pharmaceutical Inc. | $123,577 | 0 |
| PalynqiqTM and PKU Treatment Impacts on Diet Quality, Neurologicial health, nutritional status and the metabolome | BioMarin Pharmaceutical Inc. | $82,912 | 0 |
| A Non-Interventional Observational Study of Pegvaliase-Naive Adults with Phenylketonuria (PKU): Concept Elicitation and Cognitive Interviews | BioMarin Pharmaceutical Inc. | $60,038 | 0 |
| MPS VI Clinical Surveillance Program CSP) | BioMarin Pharmaceutical Inc. | $59,498 | 0 |
| PalynziqTM and PKU Treatment Impacts on Diet Quality Neurological health Nutritional Status and the Metabolome | BioMarin Pharmaceutical Inc. | $56,722 | 0 |
| A Phase 3b, Open-Label, Single Arm, Multi-Centre Study to Assess the Safety and Efficacy of Pegvaliase (BMN 165) Treatment in adults With Phenylketonuria Not Controlled With Current Management | BioMarin Pharmaceutical Inc. | $54,895 | 0 |
| A Non-Interventional Observational Study of Pegvaliase-Naive Adults with Phenylketonuria PKU Concept Elicitation and Cognitive Interviews | BioMarin Pharmaceutical Inc. | $52,119 | 0 |
| Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects with Phenylketonuria and Plasma Phe Levels > 600 umol/L | BioMarin Pharmaceutical Inc. | $34,767 | 0 |
Top Doctors Receiving Payments for Palynziq
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Salt Lake City, UT | $13.4M | 1,451 |
| , MD | Clinical Genetics (M.D.) | Chicago, IL | $183,585 | 314 |
| , M.D | Pediatrics | Houston, TX | $152,267 | 218 |
| , MD | Clinical Biochemical Genetics | Portland, OR | $95,160 | 65 |
| , FNP-C | Family | Detroit, MI | $87,260 | 190 |
| , M.D | Clinical Genetics (M.D.) | Galveston, TX | $72,491 | 114 |
| , MD | Clinical Genetics (M.D.) | Gainesville, FL | $62,430 | 41 |
| , MSN, APRN, FNP-BC | Family | Westbrook, CT | $55,604 | 168 |
| , M.D | Clinical Genetics (M.D.) | Tampa, FL | $52,577 | 60 |
| , M.D | Neurodevelopmental Disabilities | Haddonfield, NJ | $43,411 | 88 |
| , MD | Clinical Genetics (M.D.) | Indianapolis, IN | $37,152 | 65 |
| , MD | Clinical Biochemical Genetics | Salt Lake City, UT | $35,209 | 30 |
| , APN | Nurse Practitioner | Chicago, IL | $34,341 | 74 |
| , NP | Pediatrics | Ada, MI | $32,404 | 84 |
| , MD | Clinical Genetics (M.D.) | Scottsdale, AZ | $28,525 | 74 |
| , MD | Infectious Disease | Portland, OR | $28,463 | 11 |
| , M.D | Neurodevelopmental Disabilities | Salt Lake City, UT | $27,679 | 15 |
| , M.D | Clinical Biochemical Genetics | Chestnut Hill, MA | $26,365 | 43 |
| , MD | Clinical Genetics (M.D.) | Aurora, CO | $25,009 | 52 |
| , MD | Clinical Genetics (M.D.) | New Orleans, LA | $23,824 | 50 |
| Cristel Chapel-Crespo | Clinical Genetics (M.D.) | Orange, CA | $20,632 | 39 |
| , APNP | Family | Brookfield, WI | $20,061 | 65 |
| , MD, PHD | Pediatric Infectious Diseases | Philadelphia, PA | $18,150 | 5 |
| , MB CHB | Medical Biochemical Genetics | Washington, DC | $17,954 | 19 |
| , MD | Endocrinology, Diabetes & Metabolism | Dallas, TX | $17,590 | 31 |
Ad
Manufacturing Companies
- BioMarin Pharmaceutical Inc. $14.8M
Product Information
- Type Drug
- Total Payments $14.8M
- Total Doctors 387
- Transactions 4,358
About Palynziq
Palynziq is a drug associated with $14.8M in payments to 387 healthcare providers, recorded across 4,358 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2018 to 2024. In 2024, $314,174 was paid across 499 transactions to 142 doctors.
The most common payment nature for Palynziq is "Unspecified" ($13.2M, 89.0% of total).
Palynziq is associated with 20 research studies, including "Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU Prism302" ($3.2M).